The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis

In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide dose‐dependently reduced HbA1c and body weight in patients with type 2 diabetes. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Jonathan M., Lin, Yanzhu, Luo, M. Jane, Considine, Gary, Cox, Amy L., Bowsman, Lenden M., Robins, Deborah A., Haupt, Axel, Duffin, Kevin L., Ruotolo, Giacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292792/
https://www.ncbi.nlm.nih.gov/pubmed/34542221
http://dx.doi.org/10.1111/dom.14553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292792/
https://www.ncbi.nlm.nih.gov/pubmed/34542221
http://dx.doi.org/10.1111/dom.14553

Ejemplares similares